Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company at the forefront of developing innovative bi-functional fusion proteins. These unique proteins represent a new class of biologic medicine aimed at treating patients with cancer and autoimmune diseases. Shattuck's proprietary Agonist Redirected Checkpoint (ARC®) platform is designed to inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic, a groundbreaking approach in the biotechnology field.
The company's lead product candidate, SL-172154 (SIRPα-Fc-CD40L), is engineered to block the CD47 immune checkpoint and activate the CD40 pathway simultaneously. Currently, SL-172154 is in multiple Phase 1 clinical trials targeting various cancers, including platinum-resistant ovarian cancer and acute myeloid leukemia (AML). Another promising candidate, SL-279252 (PD1-Fc-OX40L), is being developed in collaboration with Takeda Pharmaceuticals and is also in Phase 1 trials.
Shattuck Labs recently embarked on an exciting collaboration with Ono Pharmaceutical to develop bifunctional fusion proteins for autoimmune and inflammatory diseases. This partnership includes a significant financial package with potential milestone payments and royalties, reinforcing Shattuck's strong financial condition and innovative capabilities. Additionally, the company's proprietary gamma delta T cell engager platform, GADLEN™, promises to bridge gamma delta T cells to tumor antigens, offering new hope for cancer treatment.
Recent achievements include rapid enrollment in clinical trials and the FDA's orphan drug designation for SL-172154, highlighting the urgent need for new AML treatments. Shattuck is also actively participating in several high-profile conferences, sharing their latest research and clinical progress. The company is headquartered in Austin, Texas, and Durham, North Carolina, and continues to leverage its scientific expertise to address unmet medical needs.
- Core Business: Development of bi-functional fusion proteins for cancer and autoimmune diseases.
- Recent Achievements: FDA orphan drug designation for SL-172154, collaboration with Ono Pharmaceutical.
- Current Projects: Phase 1 trials for SL-172154 and SL-279252, development of GADLEN™ platform.
- Financial Condition: Strong financial backing with potential milestone payments from partnerships.
- Partnerships: Collaborations with Ono Pharmaceutical and Takeda Pharmaceuticals.
Shattuck Labs, a clinical-stage biotechnology company (NASDAQ: STTK), will participate in the 11th Annual SVB Leerink Global Healthcare Conference from February 14-18, 2022. CEO Taylor Schreiber will present on February 18 at 10:40 a.m. EST. The company focuses on developing bi-functional fusion proteins for treating cancer and autoimmune diseases, currently conducting three Phase 1 clinical trials, including its SL-172154 and SL-279252 programs. A live webcast of the presentation will be available on their website, with a replay accessible for 90 days.
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology firm, announced its participation in two virtual investor conferences this January 2022. CEO Taylor Schreiber will present at the H.C. Wainwright BioConnect 2022 Conference on January 10 at 7:00 a.m. EST and the 40th Annual J.P. Morgan Healthcare Conference on January 13 at 11:15 a.m. EST. The company is advancing bi-functional fusion proteins targeting cancer and autoimmune diseases, with three ongoing Phase 1 clinical trials. Webcasts will be available live and archived for 90 days on their website.
Shattuck Labs, a clinical-stage biotechnology company (NASDAQ: STTK), is set to present at the TIGIT Therapies Digital Summit 2021 from December 7-9. CEO Taylor Schreiber will present on December 9 at 9:30 a.m. EST, discussing TIGIT blockade in refractory tumors. Shattuck is advancing bi-functional fusion proteins targeting cancer and autoimmune diseases, with three ongoing Phase 1 trials. The presentation will be available for download on the company's website and to registered participants of the summit.
Shattuck Labs announced promising Phase 1 trial data for SL-172154 targeting ovarian cancer and SL-279252 for solid tumors at the SITC annual meeting. Both trials show favorable safety profiles and evidence of immune activation. An open IND for SL-172154 in acute myeloid leukemia was also disclosed. However, Shattuck and Takeda terminated their collaboration agreement. The company's Q3 financial results reveal a net loss of $17.4 million, up from $11.8 million year-over-year, with cash reserves sufficient to fund operations into 2024.
Shattuck Labs (NASDAQ: STTK) reports promising initial data from its Phase 1 clinical trials for two compounds, SL-172154 and SL-279252, targeting advanced cancers. SL-172154 shows favorable safety, high CD47 target occupancy, and potential for use in treating acute myeloid leukemia and myelodysplastic syndromes. SL-279252 exhibited anti-tumor activity in heavily pretreated melanoma patients, including one confirmed partial response. The data will be showcased at the Society for Immunotherapy of Cancer's annual meeting and discussed in a conference call on November 12, 2021.
Shattuck Labs, Inc. (NASDAQ: STTK), a biotechnology company, will host a live webcast on November 12, 2021, at 8:00 a.m. ET, to present clinical data from ongoing Phase 1 trials. The event features CEO Taylor Schreiber along with other executives discussing their lead bi-functional fusion proteins. Highlights include data for SL-172154 in ovarian cancer and SL-279252 in solid tumors and lymphoma. The presentation will be accessible via conference call and archived online for 90 days.
Austin-based Shattuck Labs (STTK) is a clinical-stage biotechnology company focused on bi-functional fusion proteins for treating cancer and autoimmune diseases. They have three ongoing Phase 1 clinical trials and announced participation in four upcoming virtual investor conferences this November. Key presentations include the Berenberg US CEO Conference on November 10 and the Cowen IO Next Summit on November 15, featuring CEO Taylor Schreiber. A live webcast of these events will be available on their website, with replays archived for 90 days.
Shattuck Labs (NASDAQ: STTK) has appointed Dr. Carrie Brownstein as a new Board member, succeeding Josiah Hornblower, the founder and former Chairman. Dr. Brownstein brings extensive experience from her role as Chief Medical Officer at Cellectis and past positions at major pharmaceutical companies. George Golumbeski, Ph.D., has been appointed as the new Chairman of the Board. This management change is expected to enhance Shattuck's strategic growth as it advances its clinical programs, particularly the SL-172154 candidate.
Shattuck Labs (NASDAQ: STTK) announced it will present four posters at the SITC’s 36th Annual Meeting from November 10-14, 2021. The presentations will cover key studies, including a Phase 1 trial of SL-172154 for platinum-resistant ovarian cancer and SL-279252 for advanced solid tumors. The company's proprietary Agonist Redirected Checkpoint (ARC®) platform aims to enhance cancer treatment by simultaneously blocking immune checkpoints and activating costimulatory pathways. These presentations highlight Shattuck's ongoing commitment to innovative cancer therapies.
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotech firm, announced its participation in three virtual investor conferences in September 2021. CEO Taylor Schreiber will lead discussions at the Citi 16th Annual BioPharma Virtual Conference on September 9, the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, and the Morgan Stanley 19th Annual Global Healthcare Conference on September 15. The company's innovative therapies focus on cancer and autoimmune diseases, including lead programs evaluated in Phase 1 trials.
FAQ
What is the current stock price of Shattuck Labs (STTK)?
What is the market cap of Shattuck Labs (STTK)?
What is Shattuck Labs, Inc.'s core business?
What are the main product candidates of Shattuck Labs?
What is the ARC® platform?
Who are Shattuck Labs' key partners?
Where is Shattuck Labs headquartered?
What is SL-172154?
What recent achievements has Shattuck Labs made?
What is the GADLEN™ platform?
What financial condition is Shattuck Labs in?
What are some upcoming events for Shattuck Labs?
